<sup>90</sup>Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide - Concepedia

Concepedia

Publication | Open Access

<sup>90</sup>Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide

DOI Full Paper Access

303

Citations

27

References

2010

Year

David Bushnell, Thomas M. O’Dorisio, M. Sue O’Dorisio, Yusuf Menda, Rodney J. Hicks, Eric Van Cutsem, J.-L. Baulieu, Françoise Borson‐Chazot, Lowell Anthony, Al B. Benson,

Journal of Clinical Oncology

Abstract

(90)Y-edotreotide treatment improved symptoms associated with malignant carcinoid among subjects with no treatment alternatives. Treatment was well-tolerated and had an acceptable expected AE profile.

References

	Year	Citations
Nonparametric Estimation from Incomplete Observations Edward L. Kaplan, Paul Meier Journal of the American Statistical Association EngineeringAgingLife PredictionRare Event EstimationMortality Rates	1958	38.7K
A 5‐decade analysis of 13,715 carcinoid tumors Irvin M. Modlin, Kevin D. Lye, Mark Kidd Cancer	2003	2.7K
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria Stephanie Green, Geoffrey R. Weiss Investigational New Drugs OncologyToxicity CriteriaCancer ManagementSouthwest Oncology GroupClinical Endpoint	1992	613
Updated Population-Based Review of Carcinoid Tumors Melinda A. Maggard, Jessica B. O Connell, Clifford Y. Ko Annals of Surgery	2004	551
Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center Eva Tiensuu Janson, Lars Holmberg, Mats Stridsberg, Annals of Oncology Prognostic FactorsSurgical OncologyTumoral PathologyReferral CenterMedicine	1997	458
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. Christian Waldherr, Miklos Pless, Helmut R. Maëcke, PubMed	2002	446
Phase II/III Study of Doxorubicin With Fluorouracil Compared With Streptozocin With Fluorouracil or Dacarbazine in the Treatment of Advanced Carcinoid Tumors: Eastern Cooperative Oncology Group Study E1281 Weijing Sun, Stuart R. Lipsitz, Paul J. Catalano, Journal of Clinical Oncology	2005	355
Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. R. Arnold, Michael Trautmann, W. Creutzfeldt, Gut	1996	345
Yttrium-90 DOTATOC: first clinical results Andreas Otte, R. Herrmann, A. Heppeler, European Journal of Nuclear Medicine and Molecular Imaging MedicineClinical EvidenceYttrium-90 DotatocDiagnostic Sciences	1999	323
Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors Roelf Valkema, Stanislas Pauwels, Larry K. Kvols, Seminars in Nuclear Medicine MedicineRadionuclide TherapyPathologyRadiopharmaceutical TherapyCancer Treatment	2006	313

Page 1